View source for Costeffectiveness evaluation evaluating PARP inhibitorsforall on the biomarkerdirected use of PARP inhibitor maintenance treatments for fresh recognized advanced point ovarian cancer
From EECH Central
You do not have permission to edit this page, for the following reasons:
You can view and copy the source of this page.